197 related articles for article (PubMed ID: 23924796)
1. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
2. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
[TBL] [Abstract][Full Text] [Related]
3. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.
Agersø H; Overgaard RV; Petersen MB; Hansen L; Hermit MB; Sørensen MH; Petersen LC; Hilden I
Eur J Pharm Sci; 2014 Jun; 56():65-9. PubMed ID: 24568891
[TBL] [Abstract][Full Text] [Related]
5. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
6. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
[TBL] [Abstract][Full Text] [Related]
7. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
[TBL] [Abstract][Full Text] [Related]
9. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
[TBL] [Abstract][Full Text] [Related]
10. Complex PK-PD of an engineered IL-15/IL-15Rα-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics.
Lu D; Yadav R; Holder P; Chiang E; Sanjabi S; Poon V; Bernett M; Varma R; Liu K; Leung I; Bogaert L; Desjarlais J; Shivva V; Hosseini I; Ramanujan S
Eur J Pharm Sci; 2023 Jul; 186():106450. PubMed ID: 37084985
[TBL] [Abstract][Full Text] [Related]
11. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
[TBL] [Abstract][Full Text] [Related]
12. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Tabuchi H; Katsurabara T; Mori M; Aoyama M; Obara T; Yasuda N; Kawano T; Imai T; Ieiri I; Kumagai Y
J Clin Pharmacol; 2019 May; 59(5):688-701. PubMed ID: 30575978
[TBL] [Abstract][Full Text] [Related]
14. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
15. Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.
Ding Q; von Schaewen M; Hrebikova G; Heller B; Sandmann L; Plaas M; Ploss A
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928007
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
[TBL] [Abstract][Full Text] [Related]
17. EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells.
Charrin S; Le Naour F; Labas V; Billard M; Le Caer JP; Emile JF; Petit MA; Boucheix C; Rubinstein E
Biochem J; 2003 Jul; 373(Pt 2):409-21. PubMed ID: 12708969
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
[TBL] [Abstract][Full Text] [Related]
19. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
[TBL] [Abstract][Full Text] [Related]
20. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
